[Advances in genome editing technologies for treating muscular dystrophy.]

Area of Science:

• Biotechnology
• Genetics
• Molecular Biology

Background:

• Duchenne muscular dystrophy (DMD) is a severe genetic disorder caused by mutations in the dystrophin gene.
• Genome editing technologies present a potential therapeutic strategy for DMD by correcting these mutations.

Purpose of the Study:

• To review the current status of genome editing applications for Duchenne muscular dystrophy.
• To discuss future perspectives and challenges for clinical translation.

Main Methods:

• Review of existing scientific literature on genome editing for DMD.
• Analysis of studies demonstrating dystrophin gene restoration in patient-derived cells and functional recovery in animal models.

Main Results:

• Successful restoration of the mutated dystrophin gene in induced pluripotent stem cells (iPSCs) from DMD patients.
• Demonstrated functional recovery, such as improved grip strength, in mouse models of DMD.

Conclusions:

• Genome editing shows significant potential for treating DMD.
• Key challenges for clinical application include efficient delivery, minimizing off-target mutations, and managing immunogenicity.